SNDX

Axatilimab (SNDX-6352)

Chronic graft versus host disease (cGVHD)

Phase 1/2

Exp Date

Q4 2020

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: SNDX-6352-503 in Chronic graft versus host disease (cGVHD) -  Phase 1 Results

  • ClinicalTrial.gov (NCT03604692): A Phase 1/2 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 1 Results


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION / RATIONALE

  • Axatilimab (SNDX-6352) is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be a key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD (Learn more HERE). 

Updated by HC

#SNDX, #Axatilimab, #SNDX-6352, #Chronic graft versus host disease, #cGVHD, #graft versus host disease, #bone marrow, #stem cell, #transplant, #white blood cell, #WBC, 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon